Guidance for industry on flexible approaches to regulation the Medicines and Healthcare Agency (MHRA) are taking during the COVID-19 outbreak | Fieldfisher
Skip to main content
Select location
Insight

Coronavirus: What is the MHRA doing?

06/04/2020
Close-up of various measurement instruments used in a laboratory setting. The image features clear cylindrical tubes marked with measurement scales in milliliters. The colors are predominantly shades of blue and pink, giving the scene a vibrant hue.

Locations

Ireland

Guidance for industry on flexible approaches to regulation the Medicines and Healthcare Agency (MHRA) are taking during the COVID-19 outbreak. The MHRA are working closely with the Department of Health and Social Care (DHSC) and other healthcare partners and stakeholders to rapidly develop a package of ‘flexibilities’ to regulatory guidance, in order to support the medicines supply chain and wider healthcare response to the COVID-19 outbreak in the UK.

These regulatory flexibilities are:
 
  • temporary and will be kept under review, except where regulatory extensions have been stated
  • offered to provide flexibility in exceptional circumstances 
  • effective immediately

See the full guidance here. 
 
We are all navigating uncharted waters as business and society faces up to the impact of COVID-19.  We very much hope you and your loved ones remain in good health. 

 Please be assured that Fieldfisher is continuing to work with clients to navigate COVID-19 related issues and on business as usual needs.  Do get in touch with us if you would like to chat anything through.

 

Related Work Areas

Life Sciences